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Multipotent mesenchymal stromal cells (MSCs) have emerged as a promising therapy for autoimmune diseases, including multiple
sclerosis (MS). Administration of MSCs to MS patients has proven safe with signs of immunomodulation but their therapeutic
efficacy remains low.The aim of the current study has been to further characterize the immunomodulatory mechanisms of adipose
tissue-derivedMSCs (ASCs) in vitro and in vivo using the EAEmodel of chronic brain inflammation inmice.We found thatmurine
ASCs (mASCs) suppress T cell proliferation in vitro via inducible nitric oxide synthase (iNOS) and cyclooxygenase- (COX-) 1/2
activities. mASCs also prevented the lipopolysaccharide- (LPS-) induced maturation of dendritic cells (DCs) in vitro.The addition
of the COX-1/2 inhibitor indomethacin, but not the iNOS inhibitor L-NAME, reversed the block in DC maturation implicating
prostaglandin (PG) E
2
in this process. In vivo, early administration of murine and human ASCs (hASCs) ameliorated myelin
oligodendrocyte protein- (MOG
35−55
-) induced EAE in C57Bl/6 mice. Mechanistic studies showed that mASCs suppressed the
function of autoantigen-specific T cells and also decreased the frequency of activated (CD11c+CD40high and CD11c+TNF-𝛼+) DCs
in draining lymph nodes (DLNs). In summary, these data suggest thatmASCs reduce EAE severity, in part, through the impairment
of DC and T cell function.
1. Introduction
Multipotent mesenchymal stromal cells (MSCs) are non-
hematopoietic, perivascular cells which support hemato-
poiesis and are thought to participate in tissue repair in vivo
[1–3]. MSCs can be obtained from virtually all tissues and
organs of the body and have been defined in vitro as plastic
adherent cells that express CD73, CD90, and CD105 while
lacking expression of CD45, CD34, and CD14, which can
differentiate into osteoblasts, adipocytes, and chondroblasts
in vitro [4]. Although the proportion of bona fide stem cells
within MSC preparations is likely to be low [5], it has been
clearly shown that in vitro-expanded MSCs possess potent
immunomodulatory properties. Firstly, MSCs can modulate
the activation of cells of both the innate and adaptive immune
system in vitro. Depending on species and immune cell
studied, this immunomodulatory effect is achieved through
a combination of mechanisms including cytokines (IL-10,
TGF-𝛽1, and IL-6), intracellular enzymes (inducible nitric
oxide synthase (iNOS) inmurineMSCs and indoleamine 2,3-
dioxygenase (IDO) in humanMSCs), growth factors (hepato-
cyte growth factor, vascular endothelial growth factor),mem-
brane bound molecules (programmed death ligand-1, FASL),
and prostaglandin E2 (PGE
2
) [6–8]. Secondly, injection of
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MSC preparations has shown delay allograft rejection [9, 10]
and ameliorating disease in several animal models of inflam-
mation/autoimmunity by inhibiting the deleterious immune
responses against self-antigens [11–14]. Based on their success
in experimental models, the clinical potential of human
autologous and allogeneicMSCs for the treatment of autoim-
mune/inflammatory diseases has been assessed in various
phase I/II and III clinical trials [15–19].
Multiple sclerosis (MS) is a chronic disease of the central
nervous system (CNS) where autoreactive T cells andmacro-
phages attack and disrupt the communication between neu-
rons which result in a multitude of neurological symptoms
[20]. Several clinical trials have utilized MSCs for the treat-
ment of MS and a few of these studies have analyzed the
effects of injected MSCs on the immune status of patients
withMS. In a phase 1/2 open-safety clinical trial forMS, injec-
tions of autologousMSCs resulted in a rapid inhibition of the
immune system [17] while another study observed increased
foxp3 transcript levels in peripheral blood mononuclear cells
in MSC-treated patients [21]. These data suggest that the
therapeutic effect of MSCs in MS depends, at least partially,
upon their immunomodulatory capacity. However, while the
administration of MSCs has been proven safe, their capacity
to ameliorate MS remains poor [16, 17, 19, 22]. Therefore, it
is important to further study how MSCs can modulate the
immune system both in vitro and in vivo in order to improve
MSC-based therapies for MS [23].
Thus, the objective of the current study has been to char-
acterize the immunomodulatory properties of murine adi-
pose tissue-derived MSCs (mASC) in vitro and in vivo using
the experimental autoimmune encephalomyelitis (EAE)
model of CNS autoimmunity. EAE is a well-accepted animal
model of MS sharing both its immunological and patho-
logical features [24]. Injection of MSCs at distinct stages of
disease has been shown to inhibit disease severity in various
models of EAE, including relapsing/remitting EAE, chronic
EAE, and disease induced by adoptive transfer of encephal-
itogenic T cells [11, 25–27]. We show that mASC inhibited
T cell proliferation in vitro via iNOS and COX-1/2 activities.
Both allogeneic and xenogeneic (human) ASCs ameliorated
MOG
35−55
-induced chronic EAE in C57Bl/6 mice. Murine
ASCs reduced EAE severity through the inhibition of the
autoimmune T cell response with no increase in foxp3 Tregs.
Importantly, mASC inhibited the maturation of dendritic
cells (DCs) in vitro via COX-1/2 activity and reduced the
percentage of activatedDCs in the draining LNs of EAEmice.
Our data suggests that MSC, through their modulation of
T cell and DC function, can ameliorate inflammatory/auto-
immune CNS disease.
2. Materials and Methods
2.1. Animals. Male Balb/c (6–10 weeks) and female C57Bl/6
(6–8 weeks) (Charles River, Barcelona, Spain) were used to
initiate cultures of mASCs and for the induction of EAE,
respectively. Experimental protocols were performed accord-
ing to the National/EU Guidelines for the Care and Use of
LaboratoryAnimals inResearchwith the approval of the local
ethical committee at the Institute for Parasitology and Bio-
medicine “López-Neyra” and the central ethical committee at
the Consejo Superior de Investigaciones Cientificas (CSIC).
Mice were anesthetized before immunization using intraperi-
toneal injections of ketamine-HCl (dose at 100mg/kg) mixed
with xylazine-HCl (10mg/kg). Mice were sacrificed using
CO
2
when extracting the spinal cord for histological analyses.
In all other cases, mice were sacrificed using cervical disloca-
tion.
2.2. Isolation and Expansion of mASCs. Mesenchymal stro-
mal cells were isolated from adipose tissue as previously
described [28]. Cells were resuspended in MesenCult (Stem
Cell, Grenoble, France) containing 20%mousemesenchymal
supplements (Stem Cell) and penicillin/streptomycin (Invit-
rogen, Carlsbad, CA), plated at a density of 2-3× 104 cells/cm2





ent cells were removed after 24 hours in culture. Subsequent





. mASCs were used at passages 3–9. The
phenotypic characterization and differentiation capacity into
adipocytes, osteocytes, and chondrocytes were performed as
previously described ([28]; data not shown). Human ASCs
were obtained from Cellerix SA, Tres Cantos (Madrid),
Spain, and cultured in advanced DMEM supplemented with
10% FCS (Invitrogen), Glutamax (GIBCO, Life Technologies,
CA), and 100U/mL penicillin/streptomycin (GIBCO, Life
Technologies) as previously described [14].
2.3. Assessment of mASC-Mediated Inhibition of T Cell Pro-
liferation In Vitro. mASCs were treated with mitomycin C
(50 𝜇g/mL, Sigma Aldrich, St. Louis, MO) for 20 minutes at
37∘C and washed 3 times with complete RPMI1640 (2mM L-
glutamine, 100U/mL penicillin/streptomycin, 50𝜇M 2-mer-
captoethanol, and 10% heat-inactivated FCS, all from Invitro-
gen). Mitomycin C-treated mASCs were plated in flat botto-
med 96-well plates and allowed to adhere for 3-4 hours.Mito-
mycin C treatment of mASCs did not impact on their ability
to inhibit T cell proliferation in vitro (see Figure S1 in Supple-
mentary Material available online at https://doi.org/10.1155/
2017/2389753). Spleens from female Balb/c mice were homo-








2 × 105 cells were added to wells with or without mASCs.
Concanavalin A (ConA, 2.5 𝜇g/mL, Sigma Aldrich) was
added to cultures as a mitogenic stimulus of T cells. L-NAME
(1mM), indomethacin (20𝜇M), and L-norvaline (10mM)
(all from Sigma Aldrich) were added at the initiation of the
cocultures. After 3 days, cells were pulsed with 0.5 𝜇Ci/well
[3H]-thymidine (Perkin Elmer, Waltham, MA) for 6 hours
and harvested onto glass fiber filters using a FilterMate 96
well-harvester (Perkin Elmer). Uptake of [3H]-thymidinewas
measured on a 1450 Microbeta Trilux scintillation counter
(Wallac Oy, Turku, Finland).
2.4. Measurement of Nitrite Production. To assess iNOS
activity in mASCs, supernatants from control/stimulated
mASCs and mASC: DC cocultures were assayed for nitrite
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and 0.1% naphthyl ethylenediamine dihydrochlo-
ride in distilled H
2
O; Sigma Aldrich) was added to 100 𝜇L
culture supernatants and standard (NaNO
2
) in 96-well plates.
Plates were incubated at room temperature for 10min, and
absorbance was measured at 550 nm.
2.5. Measurement of Arginase Activity. Arginase activity was
measured as previously described [29]. Urea was used for
the standard curve. The protein concentrations of cell lysates
were measured using the bicinchoninic acid (BCA) assay
[30]. One unit of enzyme activity is defined as the amount
of enzyme that catalyzes the formation of 1mmol of urea per
min.
2.6. Induction of EAE. Female C57Bl/6 mice (6–8 weeks-
old) were immunized s.c. in the flanks with 150𝜇L of an
emulsion (75 𝜇L/flank) containing 150𝜇g MOG
35−55
(Gen-
script, Hong Kong, China) in PBS mixed with an equal
volume of complete Freund’s adjuvant (CFA) supplemented
with 4mg/mL Mycobacterium tuberculosis H37Ra (Difco,
Detroit, MI). Mice were injected i.p. with 200 ng pertussis
toxin (SigmaAldrich) in PBS on the day of immunization and
2 days later. Immunized mice were randomly distributed in
different groups. Group 1: control mice (𝑛 = 8) were injected
i.p. with PBS at the onset of disease (clinical scores: 0-1).
Group 2: control mice (𝑛 = 13) were injected i.p. with PBS
at the acute phase of disease (clinical scores: 1–3). Group 3:
Mice (𝑛 = 9) were treated i.p. with allogeneic mASCs (106
cells obtained from Balb/c mice and expanded in hypoxia) at
the onset (clinical scores: 0-1). Group 4: mice (𝑛 = 7) were
treated i.p. with allogeneic mASCs (106 cells obtained from
Balb/c mice and expanded in hypoxia) at the acute phase of
the disease (clinical scores: 2-3). Group 5: mice (𝑛 = 7) were
treated i.p. with hASCs (106 cells) at the acute phase of disease
(clinical scores: 1-2). Clinical symptoms of EAE were scored
daily using a 0–8 scale as follows: 0, no detectable signs of
EAE; 1, affected tail tonus; 2, tail paralysis; 3, mild hind leg
paresis; 4, severe hind leg paresis; 5, one hind leg paralysis; 6,
complete hind leg paralysis; 7, complete hind leg paralysis and
foreleg paresis; and 8, death. For the acquisition of cells and
tissues, another set of mice were used and sacrificed 7 days
after treatment with PBS or mASCs as described below. Mice
were scored daily for disease symptoms. Water gel products
providing water and moistened food pellets were placed on
the cage floor in Petri dishes which were changed daily
to prevent dehydration. Mice were euthanized if exhibiting
severe hind leg paralysis and foreleg paresis (a clinical score
of 7).
2.7. Histological Analysis of Cell Infiltration and Demyeliniza-
tion. Spinal cords from EAE mice treated i.p. with PBS (𝑛 =
4) or allogeneic mASC (𝑛 = 4) at the onset of disease (clinical
scores: 0-1) were removed 7 days after treatment and pro-
cessed for immunohistochemistry and Klüver-Barrera stain-
ing. For light microscopy, cervical and lumbar spinal cord
segments were fixed with buffered 10% formalin for 48 h and
processed for paraffin inclusion and sectioning. Transversal
sections (4 𝜇m thickness) were stained with Luxol fast blue,
cresyl violet, and hematoxylin following the Klüver-Barrera
technique [31] and were analyzed for the presence of areas of
demyelination and cell infiltration using a light microscope
(Olympus, Tokyo, Japan). For immunohistochemistry, spinal
cord sections were obtained as described for paraffin pro-
cessing followed by blocking steps with peroxidase blocking
reagents, heat-treated in 1mM EDTA buffer pH 8 at 95∘C
during 20min for antigenic unmasking, and incubated for
30min at room temperature with polyclonal anti-myelin
basic protein Ab (Master Diagnostica, Granada, Spain). The
immunohistochemical study was done on an Autostainer
480 (Thermo Fisher Scientific Inc., Waltham, MA) using
the polymer-peroxidase-based method and developed with
diaminobenzidine.
2.8. Assessment of Autoreactive T Cell Responses in EAE Mice.
Spleen and draining lymph node (DLN) cells from EAEmice
treated i.p. with PBS (control, 𝑛 = 4) or allogeneicmASC (𝑛 =
4) at the onset of disease (clinical scores: 0-1) were isolated
7 days after mASC injection and stimulated with MOG
35−55
(50 𝜇g/mL) or anti-CD3 (1 𝜇g/mL; 145-2C11; BDPharmingen,
San Diego, CA) at 1.5 × 106 cells/mL in flat bottomed 96-
well plates for proliferation and at 106 cells/mL in 24-well for
cytokine determination. Supernatants were collected after 48
hours and assayed for cytokine levels by ELISA. After 3 days,
cell proliferation was determined by [3H]-thymidine uptake
as described above. For intracellular cytokine staining, spleen
and DLN cell suspensions (1 × 106 cells/mL) were stimulated
with PMA (50 ng/mL) and ionomycin (0.5 𝜇g/mL; both from
SigmaAldrich) for 6 hours in the presence of 3 𝜇Mmonensin
(eBioscience, San Diego, CA) during the last three hours.
Cells were processed for FACS analysis as described below.
2.9. Isolation and Characterization of DCs from EAE Mice.
To determine the effect of mASCs on DC phenotype and
function in vivo, EAE mice were treated i.p. with PBS
(control, 𝑛 = 4) or with allogeneic mASC (𝑛 = 4) after the
onset of disease (clinical scores: 1-2), and 7 days later, DLNs
were isolated and digested with 1.6mg/mL collagenase type
IV and 0.1% DNAse I (Sigma Aldrich) in RPMI1640 medium
without supplements at 37∘C for 30 minutes. For intracellular
TNF-𝛼 staining, DLN cells were washed twice with complete
RPMI1640 and 2 × 106 cells/mouse were plated in 12-well
plates in the presence of 3 𝜇M monensin for 4 h. Cells were
gently harvested using cell scrapers, washed using FACS
buffer, and processed for intracellular staining as described
below. For TNF-𝛼 ELISA, CD11c+ DCs were immunomag-
netically purified using CD11c-microbeads (Miltenyi Biotech,
Bergisch Gladbach, Germany) from collagenase type IV-
digestedDLNs and plated at 2.5× 105 cells/mL in the presence
of LPS (1 𝜇g/mL). Supernatants were collected after 48 hours
for cytokine determinations.
2.10. Generation of BoneMarrow-Derived DCs (BM-DCs) and
mASC Cocultures. BM-DCs were generated as previously
described [32]. Briefly, 0.4 × 106 BM cells/mL from C57Bl/6
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mice were cultured in complete RPMI1640 containing 20 ng/
mL GM-CSF (Peprotech, London, UK). After 6–8 days, non-
adherent cells were harvested and CD11c+ immature DCs
were immunomagnetically purified using CD11c-microbeads
(Miltenyi Biotech) according to the manufacturer’s instruc-
tions. Cell preparations consisted of >95% CD11c+ DCs.
To assess the effect of mASCs on the maturation of DCs,
different numbers of mASCs were plated in 12-well plates
and allowed to adhere for at least 6 hours. CD11c+ DCs
(0.4 × 106 cells/well) were seeded into wells with or without
mASCs and LPS (1 𝜇g/mL) was added for 48 hours to induce
DC maturation/activation. In some experiments L-NAME
(1mM) or indomethacin (20𝜇M) was added to the DC:
mASC cocultures during maturation. DCs were harvested
from the cocultures by gently collecting the nonadherent
DCs from the adherent mASC monolayer. The acquired cells
consisted of >95% CD11c+ DC. Supernatants were collected
and assayed for cytokine levels by ELISA or NO
2
levels
by Griess assay. Cell suspensions were processed for flow
cytometry analysis of cell surface antigens or used for MLR
as described below.
2.11. Mixed Leukocyte Reaction. Spleens from BALB/c (H-
2d) were homogenized and erythrocytes lysed using the
Ammonium-Chloride-Potassium (ACK) lysis buffer. Cells
(4 × 106 cells/mL) were plated in Petri dishes and allowed
to adhere at 37∘C for 90 minutes. Nonadherent cells were
collected and used as responders. C57Bl/6 (H-2b) DCs from
the DC: mASC cocultures or purified CD11c+ DCs from the
DLNs of untreated ormASC-treated EAEmice were added in
flat bottomed 96-well plates (15000 DCs/well) together with
3 × 105 responder cells. After 4 days, cell proliferation was
determined by 3H-thymidine uptake as described above.
2.12. Flow Cytometry. Collagenase/DNAse-treated DLN cell
suspensions or mASC-cultured DCs were preincubated with
anti-Fc𝛾RII/Fc𝛾RIII mAb at 2.5 𝜇g/mL (2.4G2; BD Pharmin-
gen) and 7-aminoactinomycin D (2 𝜇g/mL; Sigma Aldrich)
and then stained with the following antibodies: CD11c-APC
(N481; eBioscience), CD40-PE (2/23), CD80-PE (16-10A1),
and/or CD86-PE (GL-1) (BD Pharmingen). For intracellular
cytokine staining cells were fixed, permeabilized, and stained
for IFN-𝛾-FITC (XMG1.2), IL-17-PE (TC11-18H10), TNF-𝛼-
PE (MP6-XT22), IL-4-PE (BVD4-1D11), and IL-10-PE (JES5-
16E3) (all from BD Biosciences, San Diego, CA) using
the BD cytofix/cytoperm kit (BD Biosciences) according to
the manufacturer’s instructions. Each sample was stained
with appropriate isotype controls. For the analysis of foxp3
expression cells were stained with CD4-FITC (GK1.5; BD
Biosciences) and subsequently processed for foxp3 staining
using the foxp3 staining kit (eBioscience) according to the
manufacturer’s instructions. Stained cells were analyzed on
a FACSCalibur flow cytometer (BD Biosciences).
2.13. Cytokine and PGE
2
ELISAs. The cytokine content in
supernatants from the mASC: splenocyte and DC cultures
were determined by sandwich ELISAs using capture/biotiny-
lated detection antibody pairs for IFN-𝛾, TNF-𝛼, IL-12p40
(BD Pharmingen), IL-10, IL-17, and CXCL10 (eBioscience).
Plates were developed using peroxidase-labelled streptavidin
(Sigma) and 2,2󸀠-azino-bis(3-ethylbenzthiazoline-6-sulpho-
nic acid) (ABTS) and read at 405 nm. PGE
2
levels in super-
natants were measured by ELISA (Cayman Chemicals, Ann
Arbor, MI) according to the manufacturer’s instruction.
2.14. Gene Expression Analysis. Total RNAwas purified using
Ultraspec (Biotecx, Huston, TX) from spinal cords isolated
from PBS-treated (control, 𝑛 = 4) or allogeneic mASC-
treated (𝑛 = 4) EAE mice (7 days after treatment) or from
mASCs stimulated with LPS (1𝜇g/mL, Sigma) or TNF-𝛼
(10 ng/mL, Peprotech) and IFN-𝛾 (10 ng/mL, BDBiosciences)
for 6, 12, and 24 hours. Total RNA (1𝜇g/sample) was reverse
transcribed using M-MuLV RT (Roche Diagnostic, Basel,
Switzerland) and randomhexamer primers. Semiquantitative
PCR and qPCR were performed using Taq polymerase
(Biotools, Madrid, Spain) or Supermix (Bio-Rad, Hercules,
CA), respectively. Primer pairs include the following: iNOS
FW: 5󸀠-GTTCTCAGCCCAACAATACAAGA-3󸀠; iNOS RV:
5󸀠-GTGGACGGGTCGATGTCAC-3󸀠; MCP-1 FW: 5󸀠-TTA-
AAAACCTGGATCGGAACCAA-3󸀠; MCP-1 RV: 5󸀠-GCA-
TTAGCTTCAGATTTACGGGT-3󸀠; TGF-𝛽1 FW: 5󸀠-TGC-
GCTTGCAGAGATTAAAA-3󸀠; TGF-𝛽1 RV: 5󸀠-AGCCCT-
GTATTCCGTCTCCT-3󸀠; IL-10 FW: 5󸀠-GGTTGCCAAGCC-
TTATCGGA-3󸀠; IL-10 RV: ACCTGCTCCACTGCCTTGCT;
IDO FW: 5󸀠-GGCTAGAAATCTGCCTGTGC-3󸀠; IDO RV:
5󸀠-AGAGCTCGCAGTAGGGAACA-3󸀠; COX-2 FW: 5󸀠-
GGGTTGCTGGGGGAAGAAATGTG-3󸀠, COX-2 RV: 5󸀠-
GGTGGCTGTTTTGGTAGGCTGTG-3󸀠; Arginase I FW: 5󸀠-
CAGAAGAATGGAAGAGTCAG-3󸀠; Arginase I RV: 5󸀠-
CAGATATGCAGGGAGTCACC-3󸀠; Foxp3 FW: 5󸀠-TTC-
ATGCATCAGCTCTCCAC-3󸀠; Foxp3 RV: 5󸀠-CTGGAC-
ACCCATTCCAGACT-3󸀠; IFN-𝛾 FW: 5󸀠-ACACTGCAT-
CTTGGTTTGC-3󸀠; IFN-𝛾 RV: 5󸀠-TTGCTGATGGCCTGA-
TTGTC-3󸀠; 𝛽-actin FW: 5󸀠-AATCGTGCGTGACATCAA-
AG-3󸀠; 𝛽-actin RV: 5󸀠-ATGCCACAGGATTCCATACC-3󸀠.
2.15. Statistical Analysis. All results are expressed as mean
(SEM) of at least 3 independent experiments unless otherwise
stated in the figure legends. The Mann–Whitney 𝑈-test was
applied on all in vivo results and cell-culture experiments to
compare nonparametric data for statistical significance. A 𝑝
value < 0.05 was considered significant.
3. Results
3.1. Immunomodulatory Mechanisms of mASCs In Vitro.
Acquiring high numbers of low passage MSCs with potent
immunosuppressive capacity is crucial for their successful
use as a therapy for inflammatory/autoimmune diseases [33].
In agreement with previous studies [34, 35], we found that
mASC expanded at low oxygen tension (5% O
2
) proliferated
at a higher rate compared to mASCs expanded at normoxia
(Figure 1(a)). Thus, we decided to culture the ASCs at 5%
O
2
and use these cells for the subsequent characterization
of their immunomodulatory functions in vitro and in vivo.
Whereas mASCs constitutively expressed TGF-𝛽1, COX-2,
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Figure 1: mASCs expanded in hypoxia maintain their immunosuppressive activities. (a) Proliferative response of mASCs expanded in
normoxia (21% O
2
) or in hypoxia (5% O
2
). mASCs were seeded at 5000 cells/cm2 in T25 flasks and counted at different time points when
reaching 70–80% of confluence. Data are shown as mean (SD) of one representative experiment out of three. ∗𝑝 < 0.05 versus 21% O
2
.
((b) and (c)) Immune phenotypic characterization of mASCs. mASCs were expanded under hypoxic conditions and then cultured with
medium (unstimulated) or stimulated with LPS (1 𝜇g/mL) or TNF-𝛼 (10 ng/mL) and IFN-𝛾 (10 ng/mL) for different time points (24 hours for
NO
2
determination). Gene expression of different immune markers was analyzed using semiquantitative PCR. iNOS activity was measured
in TNF-𝛼/IFN-𝛾-stimulated mASCs by the detection of NO
2
in culture supernatants using Griess assay. COX-1/2 activity was determined
by measuring the PGE
2
levels in culture supernatants from unstimulated mASCs. (d) Arginase activity is induced in mASC: splenocyte
cocultures. Splenocytes were culturedwith orwithoutmASCs and stimulatedwithConA for 3 days. Defined quantities of cell lysates were then
subjected to an in vitro arginase activity assay. Data are shown as mean (SEM) of 3 independent experiments. ∗𝑝 < 0.05 versus splenocytes
+ ConA. ((e), (f), and (g)) mASCs suppress T cell proliferation in vitro via iNOS and COX-1/2 but not arginase activity. Splenocytes (106
cells/mL) were stimulated with ConA (2.5 𝜇g/mL) in the presence of different numbers of mitomycin C-treated mASCs (ratio 20 : 1 for
IFN-𝛾 and CXCL10 determination). ((e) and (f)) The iNOS inhibitor L-NAME (1mM), the COX-1/2 inhibitor indomethacin (20𝜇M), and
the arginase inhibitor L-norvaline (10mM) were added to cultures when indicated. After 3 days, cell proliferation was measured by [3H]-
thymidine incorporation and (g) IFN-𝛾 and CXCL10 contents in the supernatants were determined by ELISA. Data are shown as mean
(SEM) of 3 independent experiments. ∗𝑝 < 0.05 versus mASC in (f) and ∗𝑝 < 0.05 versus ConA in (g). (h) iNOS and COX-2 activities
are increased in mASC: splenocyte cocultures. ConA-stimulated splenocytes (106 cells/mL) were cultured with mitomycin C-treated mASCs




contents measured in the culture supernatants.
Results are shown as mean (SEM) of 3 separate experiments. ∗𝑝 < 0.05 versus ConA; ∧𝑝 < 0.05 versus mASC + ConA.
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and arginase I mRNAs and PGE
2
, the expression of both IDO
and iNOS mRNA and NO
2
production was induced upon
stimulation with TNF-𝛼 and IFN-𝛾, but not LPS (Figures
1(b) and 1(c), Figure S2). Interestingly, we found a significant
induction of arginase activity in the splenocyte: mASCs
cocultures in comparison to mASCs or splenocytes cultured
alone (Figure 1(d)). Although arginase activity has been
shown to inhibit the proliferation of T cells [36], we found
that the addition of the arginase inhibitor L-norvaline did
not significantly revert the suppressive activity of mASCs
in concanavalin A- (ConA-) induced splenocyte prolifera-
tion (Figure 1(e)). In contrast, inhibition of iNOS activity
with L-NAME or of COX-1/2 activities with indomethacin
significantly alleviated the mASC-mediated suppression of
T cell proliferation (Figure 1(f)). However, none of these
inhibitors affected themASC-mediated suppression of IFN-𝛾
or the induction of CXCL10 in these cocultures (Figure 1(g)).
Since inhibition of iNOS may decrease COX-2 expression
and PGE
2
secretion [37, 38], we measured the PGE
2
levels
in mASC: splenocyte cocultures treated with L-NAME. We
found that L-NAME did not affect the production of PGE2
by mASCs and indomethacin did not modulate their iNOS
activity. In summary, these data show that low oxygen tension
increases the expansion of mASCs in vitro and that these
cells are effective in suppressing immune responses in vitro,
using both constitutive (COX-1/2) and inducible (iNOS)
mechanisms.
3.2. Therapeutic Effect of Allogeneic and Xenogeneic ASC
on Chronic EAE. We next wanted to assess the capacity of
allogeneic and xenogeneic ASCs to inhibit immune responses
in vivo. To this end, we induced chronic EAE in C57Bl/6
mice and administered mASCs to the animals at different
time points after immunization. A single injection of allo-
geneic mASC at the onset or at the acute phase of disease
significantly reduced the disease severity compared to control
animals receiving PBS (Figure 2(a)). Both early and late
injections of mASCs significantly reduced the cumulative
disease index (Figure 2(b)). Xenogeneic hASCs injected into
EAEmice during the acute phase of the disease (animals with
a mean score of 1.5) also reduced the mean clinical score
and significantly decreased the cumulative disease index
compared to control mice (Figures 2(c) and 2(d)).
3.3. Allogeneic mASCs Reduce Demyelinization and Inflam-
matory Infiltration in the Central Nervous System during EAE
Progression. We then wanted to analyze CNS tissue sections
from control and mASC-treated EAE mice for the presence
of inflammatory infiltrates and demyelinating plaques. To
this end, mASCs were injected intraperitoneally into EAE
mice after the onset of the clinical symptoms (average score
1.9 (0.4)) and spinal cords were obtained 7 days later from
mASC-treatedmice (average score 2.2 (1.9)) and controlmice
(average score 3.5 (1.1)) and processed for staining. We found
that mASC-treated mice exhibited little cell infiltration into
the CNS parenchyma and subsequently few demyelinating
plaques compared to control EAE mice (Figures 3(a) and
3(b)). Consistent with the reduced leukocyte infiltration, we
detected lower levels of IFN-𝛾, but also TGF-𝛽1, IL-10, and
foxp3 mRNAs in mASC-treated mice compared to control
EAE mice (Figure 3(c)).
3.4. Allogeneic mASCs Inhibit MOG-Specific Immune Res-
ponses but Do Not Induce foxp3+ Tregs. In both EAE and
MS, autoreactive Th1 and Th17 cells producing IFN-𝛾 and
IL-17, respectively, infiltrate the CNS and promote disease,
whereas treatments that induce a skewing towards an IL-
4 dominated Th2 response generally suppress EAE [39].
mASC treatment significantly reduced the number of IFN-
𝛾- and IL-17-secreting cells in both DLNs and spleen in
EAE mice (Figure 4(a) and representative gating strategy in
Figure S3). Moreover, there was a significant reduction in
the MOG
35−55
-specific recall response, with respect to both
proliferation and production of IFN-𝛾 and IL-17 compared
to control EAE mice. The effect was antigen specific since
activation of total T cells with anti-CD3Abswhich resulted in
similar proliferation and cytokine production by both groups
(Figures 4(b) and 4(c)). However, we could not detect an
increase in the anti-inflammatory cytokines IL-10 and IL-4 in
mASC-treated mice compared to control mice (Figure 4(a)),
suggesting that the mASCs did not induce a skewing towards
a Th2 response or IL-10 producing Tregs. In addition, we
could not detect any change in the size of the CD4+foxp3+
T cell population in DLNs or spleens of mASC-treated EAE
mice compared to control mice (Figure 4(d)).
3.5. mASCs Inhibit the Maturation/Activation of Dendritic
Cells In Vitro and In Vivo. Considering the importance of
DCs in the initiation of the autoimmune response seen in
EAE andMS [40], we decided to evaluate the effect of mASC
on the DC activation in vitro and in vivo. To this end, we
cocultured BM-derived immature DCs with different num-
bers of mASCs in the presence of LPS. We found that
mASC significantly inhibited the LPS-induced expression of
CD40 and TNF-𝛼 while not affecting the induction of CD80
and CD86 or the production of IL-10 or IL-12 by BM-DCs
(Figure 5(a) and representative gating strategy in Figure S4).
This partial block of DC maturation resulted in a significant
decrease in their T cell activating capacity (Figure 5(b)). Since
both iNOS and PGE
2
inhibited the proliferation of spleno-
cytes in vitro and can modulate DC activation [41–44],
we set out to investigate their involvement in the mASC-
mediated inhibition of DC maturation. We found that addi-
tion of indomethacin but not L-NAME significantly reversed
the mASC-mediated suppression of TNF-𝛼 production and
CD40 expression resulting in a significant increase in their
immunostimulatory capacity (Figure 5(c)).These effects were
observed despite the presence of iNOS activity in the mASC:
DC cocultures (Figure S2).
To study DC activation in vivo, we purified DCs from
DLNs of mASC-treated and control EAE mice 7 days after
mASC injection and analyzed their expression of costimula-
tory markers and TNF-𝛼 production. Consistent with the in
vitro data, DCs frommASC-treated EAEmice expressed sig-
nificantly lower levels of CD40, but not CD86, compared to
DCs from control EAEmice (Figure 5(d)). In addition, intra-
cellular staining of TNF-𝛼 on whole LN suspensions revealed
that mASC-treated EAEmice had fewer CD11c+TNF-𝛼+ DCs
Stem Cells International 7






































































































Figure 2: Allogeneic and xenogeneic ASC reduce EAE severity. Chronic progressive EAE was induced in C57Bl/6 mice by immunization
with MOG
35−55
. Animals were injected intraperitoneally with PBS (control) or with hypoxia-expanded allogeneic mASCs (106 cells/mouse)
either at the onset of EAE (day 11 after immunization) when the mean clinical score was 0.25 in the control group (𝑛 = 8 mice) and 0.22 in
the mASC-treated group (𝑛 = 9mice) or at the acute phase of EAE (day 15 after immunization) when the mean clinical score was 2.7 in the
control group (𝑛 = 6mice) and 2.8 in the mASC-treated group (𝑛 = 7mice). (a) Clinical symptoms were scored daily in the group treated at
onset (left panel) and at the acute phase of EAE (right panel). (b) Cumulative disease index is the sum of daily clinical scores observed between
days 20 and 40. Results are shown as mean (SD). ∗𝑝 < 0.05 versus control. (c) Human ASCs ameliorate EAE. Mice with MOG-induced EAE
were intraperitoneally injected with PBS (control, 𝑛 = 7) or with hASCs expanded in hypoxia (106 cells/mouse, 𝑛 = 6mice) during the acute
phase of the disease (arrow) when themean clinical score was 1.5 in both groups. Clinical symptoms were scored daily. (d) Cumulative disease
index is the sum of daily clinical scores observed between days 20 and 40. Results are shown as mean (SD). ∗𝑝 < 0.05 versus control.
compared to control EAE mice (Figure 5(d) and represen-
tative dot plots in Figure S5). In order to further analyze
DC function we purified CD11c+ cells from the DLNs of
control andmASC-treated EAEmice and assessed their TNF-
𝛼 producing capacity upon LPS restimulation in vitro. We
found that DCs from mASC-treated animals produced less
TNF-𝛼 upon LPS stimulation in vitro compared to control
DCs (Figure 5(d)). Taken together, these data suggest that
mASC could suppress EAE partly by preventing DC function
in vivo.
4. Discussion
MSCs have emerged as a promising therapy for MS with
some studies suggesting an MSC-mediated modulation of
the aberrant immune response [17, 21]. However, the efficacy
has so far been modest warranting the search for improved
MSC culture protocols and a greater understanding of the
mechanisms behind the immunomodulatory and trophic
effects of MSCs in vitro and in vivo [16, 17, 19]. Our analysis
of the immunomodulatorymechanisms employed bymASCs









































































Figure 3: Allogeneic mASCs reduce demyelinization and inflammatory infiltration in the central nervous system during EAE progression.
MicewithMOG-induced EAEwere intraperitoneally injectedwith PBS (control, 𝑛 = 4) or withmASCs expanded in hypoxia (106 cells/mouse,
𝑛 = 4) after the onset of the clinical symptoms, and spinal cords were obtained at the peak of the disease 7 days later. ((a) and (b)) Transverse
sections of cervical and lumbar regions of spinal cord were randomly analyzed for the presence of inflammatory infiltrates and plaques of
demyelinization using the Klüver-Barrera staining (left panels) and anti-myelin basic protein immunohistochemistry (right panels). Arrows
point to areas of demyelinization. (c) Gene expression of different inflammatory markers was determined by PCR in mRNAs isolated from
the spinal cords. Results are shown as mean (SD) of 4 mice per group. ∗𝑝 < 0.05 versus control.
cultures at 5% O
2
showed that both their iNOS and COX-1/2
activities are involved in the inhibition of T cell proliferation
in vitro. Although iNOS is used only by murineMSCs, COX-
1/2 activity has been shown to be important for the immu-
nomodulatory capacity of bothmurine andhumanMSCs [29,
45, 46]. In addition to iNOS and COX-1/2, we also detected
a significant induction of arginase activity in themASC: sple-
nocyte cultures, which was found predominantly in the
adherent splenocyte fraction and not in the mASC popula-
tion (Figure S6). This is in agreement with our recent finding
that MSCs can induce arginase I+ regulatory macrophages in
vitro [29]. Although arginase activity does not appear to be
important for theMSC-mediated inhibition of T cell prolifer-
ation in vitro, the role of MSC-educated macrophages and/or
microglia in controlling autoimmune-mediated inflamma-
tion in the CNS remains to be elucidated [47, 48].
In agreement with previous studies [11, 27], we found
that early injection of mASCs reduced the activation of
MOG
35−55
-specific T cells and significantly inhibited EAE
progression and severity.
Regulatory T cells (Tregs) control the severity of EAE
through the prevention of T cell expansion in the DLNs [49]
and by inhibiting activated T cells in the CNS [50]. Several
studies have reported an increased frequency of Tregs in the
LNs of EAE animals treated withMSCs [26, 51]. Interestingly,
two studies observed an increase in Treg number [17] or
foxp3 mRNA [21] in PBMCs from MS patients after MSC
administration. In contrast, we did not observe an increased




























































































































































































































































Figure 4: AllogeneicmASCs inhibitMOG-specific immune responses but do not induce foxp3+ Tregs.mASCswere injected intraperitoneally
inMOG-induced EAEmice after the onset of the clinical symptoms and spleens and DLNs were isolated at the peak of the disease. Untreated
EAE mice were used as controls. (a) The percentages of cytokine-producing cells in spleen and DLNs were determined by intracellular flow
cytometry as described inMaterials andMethods. ((b) and (c))DLN and spleen cells were culturedwithmedium (unstimulated) or stimulated
withMOG
35−55
(50 𝜇g/mL) or anti-CD3 (1 𝜇g/mL, used as unspecific stimulation). Proliferation was measured after 3 days by [3H]-thymidine
incorporation (b). The content of cytokines was determined in culture supernatants after 48 hours (c). (d) The percentages of CD4+Foxp3+
T cells in spleen and DLNs were determined by flow cytometry. Results are shown as mean (SD) from 4 mice per group. ∗𝑝 < 0.05 versus
control.
frequency of CD4+foxp3+ T cells or IL-10+ cells in spleen and
lymph nodes nor increased foxp3 mRNA levels in the CNS
after mASC injection into EAE mice which is in accordance
with other studies on MSCs and EAE [27, 52, 53]. These dis-
crepancies could be due to differences in the immunomod-
ulatory mechanisms employed by murine and humanMSCs,
underlying differences in the pathophysiologicalmechanisms
between EAE and MS, and the timing of MSC injection
relative to disease progression and to the numbers of MSCs
reaching the DLNs [26, 51]. These differences could also
partially explainwhy the clinical efficacy ofMSCs inMS is not
quite established. Importantly, in another MS-trial, Connick
et al. [54] observed a cessation of the protective effects six
months after intravenous infusion of MSC, suggesting that
a possible induction of Tregs by MSCs was not enough to
restore immune homeostasis in MS patients. Future studies
10 Stem Cells International
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Figure 5: mASCs inhibit the maturation/activation of dendritic cells in vitro and in vivo. (a) mASCs inhibit the maturation of DCs in vitro.
Bone marrow-derived DCs from C57BL/6 mice (4 × 105 cells/well) were matured/activated with LPS (1𝜇g/mL) in the absence or presence
of different numbers of mASCs. After 48 hours, nonadherent or loosely adherent cells were harvested (>95% CD11c+ DCs) and analyzed for
surface expression of CD40, CD80, and CD86, and the culture supernatants were analyzed for TNF-𝛼, IL-10, and IL-12 content by ELISA.
Data for nonstimulated immature DCs are shown as black bars. Results are shown as mean (SEM) of 3 (CD40, CD80, and CD86 FACS and
IL-12 ELISA) or 4 (IL-10 and TNF-𝛼 ELISA) independent experiments. ∗𝑝 < 0.05 versus control (no mASCs). (b) mASC-treated DCs show
impaired costimulatory activity on T cells. C57Bl/6 DCs (4 × 105 cells) were LPS-matured in the absence (control) or presence of mASCs (2 ×
105 cells) for 48 hours and then added to allogeneic BALB/c splenocytes (used as responders). The proliferation in the MLR was measured by
[3H]-thymidine incorporation. Results are shown asmean (SEM) of 3 independent experiments. ∗𝑝 < 0.05 versus control. (c) COX-1/2 but not
iNOS activity is partly responsible for the effect of mASCs onDCmaturation. C57Bl/6 DCs (4 × 105 cells) were LPS-matured in the absence or
presence ofmASCs (2× 105 cells) and L-NAME (1mM) or indomethacin (20𝜇M) for 48 hours. Expression of CD40was determined inCD11c+
cells by flow cytometry (5 independent experiments) and the levels of TNF-𝛼 in culture supernatants weremeasured by ELISA (3 independent
experiments). The costimulatory activity of the mASC-treated DCs was determined in a MLR using BALB/c splenocytes as responders (4
independent experiments). Results are expressed as percentage of values found with control samples treated with LPS alone in the absence
of mASCs and shown as mean (SEM) of the independent experiments. ∗𝑝 < 0.05 versus control; #𝑝 < 0.05 versus mASCs. (d) mASC
treatment impairs DC function in DLNs of EAE mice. C57BL/6 mice with initial EAE symptoms (scores 1-2) were injected intraperitoneally
with allogeneic mASCs (106 cells/mouse) isolated from BALB/c mice. After 7 days, DLN cells from untreated (mean score 4.6 (1.0)) and
mASC-treated mice (mean score 2.1 (1.0)) were analyzed for the expression of surface CD11c, CD40 (𝑛 = 8 mice/group), and CD86 (𝑛 = 5
mice/group) and intracellular TNF-𝛼 (𝑛 = 4mice/group) by flow cytometry as described inMaterials andMethods. CD11c+DCswere purified
by magnetic separation from DLNs from untreated (control) or mASC-treated mice (𝑛 = 4 mice/group), restimulated (2.5 × 105 cells/mL)
with LPS (1𝜇g/mL) for 24 hours, and the TNF-𝛼 levels in supernatants are determined by ELISA (lower right panel). Results are shown as
mean (SD). ∗𝑝 < 0.05.
are needed to elucidate if/how MSCs can induce functional
Tregs in human MS patients and to design strategies to
increase their induction.
DCs are specialized antigen presenting cells that, upon
maturation by toll like receptor ligands and cytokines, upreg-
ulate costimulatorymolecules (CD40, CD80, and CD86) and
produce cytokines (TNF-𝛼, IL-12), in order to induce appro-
priate T cell responses [55]. However, DCs also play funda-
mental roles in the induction of EAE and the severity of CNS
damage correlates with the activation status of DCs [56–58].
In MS patients, DCs can be found in CNS lesions [59] and
circulating DCs exhibit an activated CD40highTNF-𝛼+ phe-
notype [60]. Importantly, several first-line drugs forMS, such
as IFN-𝛽 [61] and glatiramer acetate [62], inhibit DC func-
tion, suggesting that DCs could represent a target for thera-
peutic modulation. It is thus important to understand if and
how MSCs can affect DC function both in vitro and in vivo.
PGE
2
has been shown to inhibit T cell proliferation directly or
indirectly through its effect on DCs [63]. Spaggiari et al. [43]
showed that BM-MSC-derived PGE
2
could inhibit early DC
differentiation but not LPS-induced DC maturation. In con-
trast, Yañez et al. [64] described that hASC inhibitedDCmat-
uration in a PGE
2
-independent manner. We found that the
mASC-derived COX-1/2, but not iNOS activity, could inhibit
the LPS-induced CD40 and TNF-𝛼 expression by DCs.These
contradictory results could be due to species differences,
source of DCs, and methodological setup as well as differ-
ences in the readout for the DC maturation state. We found
that although the expression of CD80, CD86, IL-12, and IL-10
was unaffected, mASC-educated DCs were significantly less
effective in inducing T cell proliferation.This is in accordance
with the study reported by Sá-Nunes et al. [65] showing
that exogenous PGE
2
could inhibit the LPS-induced TNF-𝛼
secretion and CD40, but not CD80 and CD86, expression on
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DCs which resulted in a decreased T cell-stimulatory ability.
In addition to PGE
2
, other COX1/2-dependent prostanoids,
including PGD
2
and its metabolite 15-deoxy-delta12,14-PGJ
2
have been shown to inhibit LPS-induced production of
proinflammatory cytokines by DCs [66, 67]. Although it is
conceivable that PGE
2
is the main suppressive prostanoid
produced byMSCs, further studies should assess the presence
of other prostanoids and PGE
2
-derived metabolites [68] and
include specific inhibitors for the PGE
2
receptors, EP1-4.
Interestingly, a recent study showed that BM-MSCs can pro-
duce PGE
2
and prostacyclin (PGI2) [69]. The expression of
both anti-inflammatory prostanoids was lost upon oncogenic
transformation of the BM-MSCs and this was paralleled with
their inability to inhibit immune responses in vitro and in
vivo. However, the role of BM-MSC-derived PGI2 in the
modulation of DC activation has not been investigated.
As discussed above, MSCs can inhibit DC function in
vitro butwhether this is also true in vivo is less known. Todate
only one clinical trial has assessed the effects ofMSCs onDCs
in vivo and found a reduction in circulating CD40+ myeloid
DCs shortly after MSC injection [17]. Using a mouse model
based on the adoptive transfer of T cells and LPS-activated
DCs, Chiesa et al. showed that BM-MSCs could inhibit the
migration and T cell priming capacity by the injected DCs
in vivo [70]. Another study using a model of bacteria-
induced hepatitis showed thatMSC administration induced a
population of CD80lowCD86low tolerogenic DCs in vivo [71].
However, only two studies have analyzed the activation state
of endogenous DCs in CFA/MOG-induced EAE after MSC
infusion with contradictory results [27, 53]. In our study,
we found that CD11c+ DCs from DLNs of mASC-treated
mice expressed lower levels of CD40, but not CD86, and
intracellular TNF-𝛼 compared to EAE control mice cor-
roborating our in vitro data. In addition, purified LN-DCs
from mASC-treated mice produced less TNF-𝛼 upon LPS
restimulation in vitro. These data suggest that MSCs can
inhibit the activation of DCs in vivo. Although not addressed
in the current study, we and others have found that injected
MSCs reachDLNs inCFA/MOG-induced EAE [27, 52].Thus,
we believe that the reduction of activated DCs in the DLNs
of MSC-treated mice is most likely a combination of (i)
reduced DC migration from the immunization site and (ii)
a direct MSC-mediated inhibition of DC activation in the
DLNs, although the relative contribution of bothmechanisms
requires further studies.
5. Conclusions
Our data suggest that allogeneic ASCs expanded in hypoxia
could represent a promising treatment of autoimmune dis-
eases, including MS, through their effects on DC activation
and autoimmune responses. It is becoming clear that DCs
represent important effector cells, mediating the beneficial
effects of MSCs in vivo. Further studies should address in
more detail the effects of MSCs on DC function in MS
patients and how to increase the MSC-mediated inhibition
of DCs. Moreover, the elucidation of the molecular mecha-
nisms involved in the immunomodulatory activity of ASCs,
especially the activation of COX-2, suggests that the adminis-
tration of COX-2 inhibitors (i.e., indomethacin or ibuprofen)
during the treatment with ASCs of patients with MS or
other autoimmune disorders could impair their therapeutic
efficacy.
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tissue-derived mesenchymal stem cells increase skin allograft
survival and inhibit th-17 immune response,” PLoS ONE, vol. 8,
no. 10, Article ID e76396, 2013.
[11] G.Constantin, S.Marconi, B. Rossi et al., “Adipose-derivedmes-
enchymal stem cells ameliorate chronic experimental autoim-
mune encephalomyelitis,” Stem Cells, vol. 27, no. 10, pp. 2624–
2635, 2009.
[12] M. D. Nicola, C. Carlo-Stella, M. Magni et al., “Human bone
marrow stromal cells suppress T-lymphocyte proliferation ind-
uced by cellular or nonspecific mitogenic stimuli,” Blood, vol.
99, no. 10, pp. 3838–3843, 2002.
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